Dr. Sagar Lonial MD Atlanta, GA with 21+ years experience
Gender: Male Years In Practice: 21+ Phone Number:(404) 778-1900
Specialty
Hematology
General Hematology
Hematologic Oncology
Contact
1365 Clifton Rd Ne
Atlanta, GA 30322 Phone:(404) 778-1900
Insurances
Aetna Choice POS II Aetna HMO BCBS Blue Card PPO BCBS Georgia Blue Choice HMO BCBS Georgia BlueChoice Option POS CIGNA HMO CIGNA Open Access CIGNA PPO First Health PPO
Great West PPO Humana ChoiceCare Network PPO Multiplan PHCS PPO Multiplan PPO Oxford Health Freedom Oxford Health Liberty United Healthcare - Direct Choice Plus POS United Healthcare - Direct Options PPO
Affiliated Hospitals
Emory University Hospital Atlanta, GA Emory University Hospital Midtown Atlanta, GA Grady Memorial Hospital Atlanta, GA
Dr. Sagar Lonial's Videos
ASH 2015: Dr. Sagar Lonial ASH Overview
Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of Hematology's (ASH) national conference this weekend. In this video, Dr. Lonial discusses the excitement at ASH about two-drug versus three-drug treatment approaches in newly diagnosed myeloma patients.
Dr. Sagar Lonial Emory University Atlanta, GA, USA
Please subscribe to our channel! Subscribe to International Myeloma Foundation:
Visit our website at:
Find us online: Facebook: Google+: IMF on twitter: @IMFMyeloma ( Dr. Durie on twitter: @BrianDurieMD (
Support the IMF! Category Nonprofits & Activism License Standard YouTube License
Dr. Sagar Lonial discusses the results from the ELOQUENT-2 Phase III clinical trial
Dr. Sagar Lonial Emory University Atlanta, GA, USA
BACKGROUND: Elo, a monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), kills myeloma cells with minimal effect on normal tissue. Elo showed encouraging activity with Len/dex (Ld) in a phase Ib/II study in pts with RRMM. This phase III study (NCT01239797) compared efficacy and safety of Elo/Len/dex (ELd) vs Ld.
CONCLUSIONS: A clinically relevant 30% reduction in risk of progression or death was seen with ELd vs Ld. More pts remain on ELd vs Ld and follow-up for long-term outcomes, including survival, is ongoing. IRs were manageable. Elo, a mAb with a novel immunotherapeutic mechanism of action, showed improved PFS, with minimal added toxicity in combination with Ld vs Ld alone, in pts with multiple myeloma. Clinical trial information: NCT01239797
Please subscribe to our channel! Subscribe to International Myeloma Foundation:
Visit our website at:
Find us online: Facebook: Google+: IMF on twitter: @IMFMyeloma ( Dr. Durie on twitter: @BrianDurieMD (
Support the IMF! Category Nonprofits & Activism License Standard YouTube License
Prof. Sagar Lonial | ASH 2017 | Highlights of ASH in RRMM
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Professor Sagar Lonial Winship Cancer Institute at Emory University, Atlanta, US
Interview topic: Highlights of ASH in R/R MM
For more information and expert opinions in Multiple Myeloma (MM) please visit: multiplemyelomahub.com